GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » ROC (Joel Greenblatt) %

VAXX (Vaxxinity) ROC (Joel Greenblatt) % : -403.89% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vaxxinity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -403.89%.

The historical rank and industry rank for Vaxxinity's ROC (Joel Greenblatt) % or its related term are showing as below:

VAXX's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -310.545
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Vaxxinity's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Vaxxinity ROC (Joel Greenblatt) % Historical Data

The historical data trend for Vaxxinity's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity ROC (Joel Greenblatt) % Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-8,580.00 -629.57 -1,111.58 -600.45 -476.73

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -638.60 -592.55 -465.67 -455.35 -403.89

Competitive Comparison of Vaxxinity's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Vaxxinity's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxxinity's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vaxxinity's ROC (Joel Greenblatt) % falls into.


;
;

Vaxxinity ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.43) - (20.23 + 0 + 0)
=-16.8

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.421) - (14.141 + 0 + 1.558)
=-13.278

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Vaxxinity for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-44.84/( ( (11.123 + max(-16.8, 0)) + (11.081 + max(-13.278, 0)) )/ 2 )
=-44.84/( ( 11.123 + 11.081 )/ 2 )
=-44.84/11.102
=-403.89 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxxinity  (OTCPK:VAXX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Vaxxinity ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Vaxxinity's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxxinity Business Description

Traded in Other Exchanges
N/A
Address
505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Executives
Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292